ArticleArthritis2014
Epicardial fat thickness as cardiovascular risk factor and therapeutic target in patients with rheumatoid arthritis treated with biological and nonbiological therapies.
Article in Arthritis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Adalimumab Reduces Epicardial Adipose Tissue in Psoriasis: A Post Hoc Analysis of a Randomized Placebo-Controlled Clinical Trial.Psoriasis (Auckland, N.Z.) · 2026Article
- Re: ID f1459919-55b0-4cf8-8c61-369db603bc92 echocardiography in collagen diseases.The international journal of cardiovascular imaging · 2025Review
- A narrative review of epicardial adipose tissue as a predictor of cardiometabolic risk in rheumatoid arthritis patients.Annals of translational medicine · 2025Review
- Prognostic Value of Epicardial Adipose Tissue in Heart Failure With Mid-Range and Preserved Ejection Fraction: A Multicenter Study.Journal of the American Heart Association · 2024Article
- Ethnic disparities and its association between epicardial adipose tissue thickness and cardiometabolic parameters.Adipocyte · 2024Article
- Increased epicardial adipose tissue thickness as a sign of subclinical atherosclerosis in patients with rheumatoid arthritis and ıts relationship with disease activity ındices.Internal and emergency medicine · 2024Article
- Article
- Epicardial adipose tissue thickness and growth differentiation factor 15 in axial spondyloarthritis: A cross-sectional study.Saudi medical journal · 2022Article
- Perivascular adipose tissue in autoimmune rheumatic diseases.Pharmacological research · 2022Review
- Article
- Epicardial adipose tissue is associated with extent of pneumonia and adverse outcomes in patients with COVID-19.Metabolism: clinical and experimental · 2021Article
- Potential Role of Atrial Myopathy in the Pathogenesis of Stroke in Rheumatoid Arthritis and Psoriasis: A Conceptual Framework and Implications for Prophylaxis.Journal of the American Heart Association · 2020Review
- Review
- Increased Epicardial Fat Volume Is Independently Associated with the Presence and Severity of Systemic Sclerosis.Academic radiology · 2017Article
- Impaired Left Ventricular Diastolic Functions and Thickened Epicardial Adipose Tissue in Rheumatoid Arthritis Patients is Correlated with DAS-28 Score.Acta Cardiologica Sinica · 2017Article
- Epicardial fat: a novel marker of subclinical atherosclerosis in clinical practice?Anatolian journal of cardiology · 2017Article
- Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study.Endocrine · 2016Article
- Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background.World journal of cardiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with high cardiovascular morbidity and mortality. Epicardial adipose tissue (EAT) thickness may act as a therapeutic target during treatments with drugs modulating the adipose tissue. We evaluate EAT thickness in RA patients treated with biological and nonbiological disease-modifying antirheumatic drugs (DMARDs). A cross-sectional study was conducted with a cohort of 34 female RA patients and 16 controls matched for age and body mass index (BMI). Plasma glucose, basal insulin, plasma lipids, and high-sensitivity C-reactive protein (hs-CRP) were assessed. EAT thickness and left ventricular mass (LVM) were measured by echocardiography. No significant differences in waist circumference (WC), blood pressure, fasting blood glucose, basal insulin, and lipid parameters were found between the groups. The control group showed lower concentrations (P = 0.033) of hs-CRP and LVM (P = 0.0001) than those of the two RA groups. Patients treated with TNF-α inhibitors showed significantly lower EAT thickness than those treated with nonbiological DMARDs (8.56 ± 1.90 mm versus 9.71 ± 1.45 mm; P = 0.04). Women with no RA revealed reduced EAT thickness (5.39 ± 1.52 mm) as compared to all RA patients (P = 0.001). Results suggest that RA patients have greater EAT thickness than controls regardless of BMI and WC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.